


**Amendments to the Claims**

This listing of claims will replace all prior versions, and listings, of claims in the application:

**Listing of Claims:**

- 1) (Currently Amended) An imaging agent which comprises a synthetic MSRA antagonist labelled with an imaging moiety, wherein the synthetic MSRA antagonist is a sulphonamidobenzamide compound of Formula (II):



wherein

z is 0, 1 or 2;

R<sup>1</sup>, R<sup>2</sup>, R<sup>4-7</sup>, R<sup>9-11</sup>, R<sup>13</sup> and R<sup>14</sup> are chosen from hydrogen, C<sub>1-6</sub> alkyl, hydroxy, carboxy, amino or halogen;

R<sup>2</sup>, R<sup>8</sup> and R<sup>12</sup> are all halogen wherein at least one of R<sup>2</sup>, R<sup>3</sup>, R<sup>7</sup>, R<sup>8</sup> and R<sup>12</sup> is said imaging moiety, and the remaining R<sup>2</sup>, R<sup>3</sup>, R<sup>7</sup>, R<sup>8</sup> and R<sup>12</sup> groups are independently selected from hydrogen, C<sub>1-6</sub> alkyl, carboxy, or a halogen selected from chlorine, bromine or iodine;  
and wherein the imaging moiety can be detected externally in a non-invasive manner following administration of said labelled synthetic MSRA antagonist to the mammalian body *in vivo*.

Appl. No. 10/537,103  
Amdt. Dated July 13, 2010  
Reply to Office Action of April 16, 2010

- 2-4) (Cancelled)
- 5) (Cancel)
- 6) (Currently Amended) The imaging agent of claim 1, wherein said imaging moiety is selected from:
- (i) ~~a radioactive metal ion;~~
  - (ii) ~~a paramagnetic metal ion;~~
  - (i) a gamma-emitting radioactive halogen;
  - (ii) a positron-emitting radioactive non-metal;
  - (v) ~~a hyperpolarised NMR active nucleus;~~
  - (vi) ~~a reporter suitable for *in vivo* optical imaging;~~
  - (vii) ~~a β-emitter suitable for intravascular detection.~~
- 7) (Cancelled)
- 8) (Cancelled)
- 9) (Cancelled)
- 10) (Cancelled)
- 11) (Withdrawn) The imaging agent of claim 6, wherein the gamma-emitting radioactive halogen is a radioactive isotope of iodine.
- 12) (Withdrawn) The imaging agent of claim 11, wherein the radioactive isotope of iodine is chosen from  $^{123}\text{I}$  or  $^{131}\text{I}$ .
- 13) (Cancelled)
- 14) (Withdrawn) The imaging agent of claim 13, wherein the positron-emitting radioactive non-metal is  $^{18}\text{F}$ .
- 15) (Cancelled)

Appl. No. 10/537,103  
Amdt. Dated July 13, 2010  
Reply to Office Action of April 16, 2010

16) (Cancelled)

17) (Cancelled)

18) (Cancelled)

19) (Cancelled)

20) (Cancelled)

21) (Previously presented) A pharmaceutical composition comprising the imaging agent of claim 1, together with a biocompatible carrier, in a form suitable for mammalian administration.

22) (Original) The pharmaceutical composition of claim 21 for use in the diagnostic imaging of cardiovascular disease.

23) (Previously presented) The pharmaceutical composition of claim 21 for use in the diagnostic imaging of atherosclerotic plaques, coronary artery disease, thrombosis, transient ischaemia or renal disease.

24) (Original) The pharmaceutical composition of claim 23 for use in the diagnostic imaging of atherosclerotic plaques.

25) (Original) The pharmaceutical composition of claim 24 for use in the diagnostic imaging of unstable atherosclerotic plaques.

26) (Previously presented) A kit for the preparation of the pharmaceutical composition of claim 21, comprising a precursor of the imaging agent of claim 1.

27) (Cancelled)

28) (Cancelled)

29) (Cancelled)

Appl. No. 10/537,103  
Amdt. Dated July 13, 2010  
Reply to Office Action of April 16, 2010

30) (Cancelled)

31) (Cancelled)

32) (Cancelled)

33) (Cancelled)

34) (Cancelled)